Serum Tumor Marker Monitoring for Breast Cancer
739
about 18 years
18+
709 sites in AK, AR, AZ +42
What this study is about
This trial is testing if using serum tumor markers to monitor hormone receptor-positive, HER2-negative metastatic breast cancer is as effective as usual monitoring. It involves measuring tumor markers and assessing quality of life while comparing the results to standard disease monitoring methods.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Anxiety Questionnaire Administration
- 2.Quality-of-Life Assessment
- 3.Use Serum Tumor Marker directed disease monitoring
- +1 more
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
You are randomly assigned, but you will know your treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Primary: Assessment of whether patients monitored with STMDDM have non-inferior overall survival compared with patients monitored with usual care
Secondary: Assessment of quality of life of patients monitored with STMDDM versus patients monitored with usual care
Oncology